Risankizumab injector study completed – no major breakthrough expected

NCT ID NCT06937619

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 1 study tested how well the drug risankizumab (SKYRIZI) is absorbed when given through an on-body injector compared to a standard injection. It involved 263 healthy adults and measured drug levels in the blood and any side effects. The goal was to see if the on-body injector delivers the drug similarly to the usual method, not to treat any disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Risankizumab (SKYRIZI)

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Acpru /Id# 271954

    Grayslake, Illinois, 60030, United States

  • CenExel ACT- Anaheim Clinical Trials /ID# 274805

    Anaheim, California, 92801, United States

  • Collaborative Neuroscience Research CNS /ID# 275212

    Los Alamitos, California, 90720, United States

  • Cpmi /Id# 274464

    Miami, Florida, 33172, United States